Abstract We have investigated the requirement for c-myc downregulation in the growth arrest of vascular smooth muscle cells (VSMCs). Rat VSMCs were infected with a retrovirus vector directing constitutive expression of either the complete human c-Myc protein (VSM-myc cells) or the c-Myc deletion mutant D106-143, which is inactive in cotransformation and autosuppression assays (VSM-D106-143 myc cells). Clones of transfected VSM-myc cells were isolated that constitutively expressed a range of levels of c-Myc protein from that observed in normal proliferating VSMCs to approximately seven times normal. The growth rates of these clones and their responses to growth inhibitors were then assessed. VSM-myc clones possessed a shorter mean intermitotic time than normal cells, which was inversely correlated (P<.05) with the level of c-Myc protein expressed. VSM-myc cells also expressed lower levels of a-smooth muscle actin mRNA and protein and exhibited an altered morphology. The proliferation of normal VSMCs and VSM-D106-143 myc cells was inhibited by serum reduction (0.5% fetal calf serum) and also by treatment with interferon-y (100 IU/mL), heparin (50 ,ug/mL), 8-bromocAMP (0.1 mmol/L), or 8-bromo-cGMP (0.1 mmol/L). In contrast, proliferation of VSM-myc cells was not inhibited by any of these agents, even if present at 10-fold higher concentrations. However, =75% of VSM-myc cells expressing levels of c-Myc protein seen in normal proliferating VSMCs underwent apoptosis after 4 days of serum reduction or treatment with interferon-y. The results show that constitutive c-myc expression induces continuous cell proliferation, reduction in a-smooth muscle actin expression and apoptosis in VSMCs. We conclude that downregulation of c-myc is a prerequisite for growth arrest and subsequent survival of VSMCs. Conversely, deregulated c-myc expression may be important in the proliferation and death of VSMCs -characteristics of the pathogenesis of atherosclerosis. (Circ Res. 1994;74:525-536.) 
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We examined the effects on the growth rates of normal VSMCs, VSM-myc cells, and VSM-D106-143 myc cells of serum reduction or the addition of the growth inhibitors heparin, INF-y, and lipid-soluble analogues of cyclic nucleotides. To discriminate between any effects of c-myc deregulation versus overexpression, we used two VSM-myc cell clones that express different steady-state levels of c-Myc protein. Clone 7 constitutively expresses levels of c-Myc protein equivalent to those in normal proliferating VSMCs (:3700 molecules per cell), and clone 13 expresses 1.5 x normal c-Myc protein levels (=6100 molecules per cell). To examine the effects of serum withdrawal, we cultured cells in 0.5% FCS. Incubation of either normal VSMCs or VSMCs expressing the defective D106-143 c-Myc protein in 0.5% FCS effectively blocked proliferation. Similarly, each of the growth inhibitors led to a decrease of :50% in the proliferation of both normal VSMCs and VSM-D106-143 myc cells (Fig 4A and 4B) ; statistically significant differences in proliferation were detectable by day 2 in all treatment groups for both cell lines (P<.05 versus control cells). In contrast, proliferation of clone 7 VSM-myc cells was not measurably inhibited by the same concentrations of heparin, 8-bromo-cAMP, or 8-bromo-cGMP (Fig 4C) . Indeed, even when the concentrations of these inhibitors were increased 10-fold, we observed no inhibition of cell proliferation (data not shown). However, both serum reduction and IFN-y treatment apparently led to a significant growth arrest of VSM-myc clone 7 cells (P<.05 versus control cells after day 2). Like clone 7, clone 13 cells (which express 1.5 x normal c-Myc protein levels) were also resistant to the growth-inhibitory effects of heparin and cyclic nucleotide analogues yet showed apparent growth inhibition in low serum (P<.05 versus control cells after day 2) (Fig 4D) . Unlike clone 7, however, clone 13 cells did not appear to be growth-inhibited by IFN-y. Thus, constitutive expression of even physiological levels of c-Myc effectively counters the antiproliferation of heparin and cyclic nucleotide analogues. However, deregulated c-Myc expression did not appear to overcome the growth-suppressive effects of low serum, and only elevated levels of c-Myc appeared to overcome the growthinhibitory effects of INF-y. In contrast, no change in the proportion of cells in S phase is evident in VSM-myc cells (clones 7 and 13) after any growth-inhibitory treatment, apart from a small reduction in S-phase cells after serum depletion of clone 7. (Table 4 ). This analysis confirmed that low serum, IFN-y, heparin, and cyclic nucleotide analogues each effectively blocked the growth of normal VSMCs and control VSM-D106-143 myc cells. In all cases, cells accumulated principally in the G, phase of the cell cycle with a concomitant reduction in the proportion of cells in S phase. In contrast, neither clone 7 nor clone 13 VSM-myc cells were growth-inhibited by either heparin or cyclic nucleotide analogues, consistent with the growth curve data described above. However, whereas low serum appeared to block proliferation of both clone 7 and 13 VSM-myc cells by growth curves, flow cytometry indicated little or no reduction in the proportion of cells in S phase. Similarly, INF-y had no effect on the proportion of clone 7 cells traversing S phase, even though it blocked any increase in cell numbers by growth curves.
We investigated the apparent discrepancy between growth curves and flow cytometry by time-lapse cinemicroscopy. The intermitotic times of dividing cells are shown in Table 5 , and the rates of cell death when treated with 0.5% FCS or IFN-y are shown in Fig 5. Cinemicroscopy showed that the proliferation of both clone 7 and clone 13 cells was not significantly inhibited in low serum or by IFN-y, in agreement with flow cytometric data. However, substantial cell death occurred by the process of apoptosis (Figs 5 and 6) , which was the reason for the apparent lack of VSM-myc cell proliferation in low-serum (clones 7 and 13) and in IFN-y--treated clone 7 cells, when assessed by growth curves. Apoptosis is characterized by a rapid sequence of morphological changes; cells first undergo retraction and shrinkage, followed by condensation of the nuclear chromatin, blebbing of the plasma membrane, nuclear fragmentation, and ultimately formation of a dense apoptotic body that may be phagocytosed by adjacent cells34 (Fig 6A) . Apoptosis was confirmed also by the To further confirm that both the resistance to growth inhibitors and the induction of apoptosis were due to the presence of deregulated c-myc expression and not due to the effects of clonal selection, VSMCs were infected with a construct encoding a conditional allele of c-Myc, a chimeric protein comprising c-Myc fused with part of the estrogen receptor. Cells expressing this Myc-ER chimera were designated VSM-myc-ER cells. In the absence of 13-estradiol, the c-Myc protein expressed by this construct is sequestered within the cell and functionally inactive; in the presence of ,B-estradiol, the retrovirus-encoded c-Myc protein is released and activated. 5, 6, 26 The expression of exogenous c-Myc protein from this construct is dependent on the addition of f3-estradiol to the culture medium6 and was in the supraphysiological range. In the absence of f3-estradiol, VSM-myc-ER cells were growth-inhibited by all of the agents tested (Fig 7A) but did not undergo significant apoptosis in low serum (Fig 8) . In the presence of /3-estradiol (2 ,umol/L), VSM-myc-ER cells were resistant to growth inhibition from heparin, cyclic nucleotide analogues, and IFN-y. The apparent suppression of proliferation of VSM-myc-ER cells with ,B-estradiol in low-serum conditions on growth curves was shown to be due to the presence of widespread cell death (Fig 8) . This was confirmed to be apoptosis on time-lapse cinemicroscopy and DNA electrophoresis (data not shown). Although serum withdrawal has no effect on VSMmyc cell proliferation, it does attenuate any increase in live cell numbers with time. This is due to apoptosis of VSM-myc cells, b-etause no significant increase in intermitotic time is noted when cells are cultured in reduced serum conditions as occurs in normal VSMCs. A similar induction of apoptosis is observed after treatment of VSM-myc cells with high levels of TFN-y in clones that express levels of c-Myc protein similar to those of normal VSMCs. That apoptosis is due to the presence of deregulated c-myc expression is also seen by the fact that VSM-myc-ER cells do not undergo apoptosis to any significant extent when cultured in low serum unless the exogenous c-Myc protein is activated by /3-estradiol.
c-myc has been implicated in apoptosis in a variety of studies. Deregulated c-myc expression in fibroblasts, myeloid cell lines, and lymphocytes is associated with an increased incidence of cell death by apoptosis.5,9,47-49 Elevation of c-myc expression also accompanies apoptosis in tissues that undergo hormone-dependent regression and in immature thymocytes. [50] [51] [52] [53] Furthermore, antisense oligonucleotides to c-myc can block T-cell receptor-triggered apoptosis in T-cell hybridomas.54 In VSMCs, as in fibroblasts,5 it thus appears that c-myc promotes concurrent proliferation and apoptosis. The regions of the c-Myc protein that are responsible for transactivation, dimerization with Max, and DNA binding are required for both proliferation and the induction of apoptosis,5'9"0 suggesting that c-myc-induced proliferation and apoptosis are due to changes in the transcription of specific genes. Which of the two processes eventually predominates appears to depend on the presence of other factors such as serum cytokines and growth inhibitors.7 Thus, the ability to induce apoptosis appears to be a normal function of c-myc within the cell.
Apoptosis is a ubiquitous normal physiological homeostatic control mechanism that regulates tissue mass and architecture in many tissues both during embryogenesis and in the adult (reviewed in References 55 through 58). Apoptosis has not hitherto been observed in VSMCs, although in view of the role of apoptosis elsewhere, it may be involved in defining and maintaining vascular architecture and cell number. Although constitutive c-Myc expression markedly accelerates VSMC apoptosis, even normal VSMCs exhibit low-level apoptosis in low serum. Apoptosis induced in low serum can be completely blocked by the addition of specific cytokines to the growth medium (authors' unpublished data) and so is not due to nutrient starvation or any other form of direct privation. Thus, modulation of normal VSMC and plaque VSMC apoptosis may be an integral part of how cell number is regulated in these cells. How much apoptosis of VSMCs occurs in vivo has not been adequately investigated, and it is possible that accumulation of VSMCs in atheromatous plaques, despite the low apparent rate of VSMC proliferation, 45, 46 may in part be due to abrogation of cell death. Apoptosis may also be involved in the progressive development of cell-poor connective tissue in more advanced plaques and contribute to the attenuation of VSMC number in those plaques that undergo rupture. Clearly, the process of apoptosis in VSMCs is worthy of further study.
In conclusion, we have shown that constitutive c-myc expression blocks VSMC growth arrest mediated in response to a variety of conditions that mimic natural growth inhibition. Deregulated c-myc expression is accompanied by reduced and altered expression of a-smooth muscle actin in VSMCs, which thus appear to have assumed a partially dedifferentiated phenotype. Such cells are common in atherosclerotic plaques and in some cases have been shown to express elevated levels of c-myc in culture. We have also shown that deregulated c-myc is a powerful inducer of apoptosis in VSMCs that are deprived of serum growth factors or exposed to high levels of IFN-y. Further analysis of the mechanisms by which c-myc induces continuous proliferation and apoptosis in VSMCs may therefore shed light on how normal VSMC growth is regulated and on the changes occurring in atherosclerosis.
